Combination Treatment for CLL
The results from a phase II multicentre study in which older (≥65 years), previously untreated patients with chronic lymphocytic leukaemia received a combination of pentostatin, cyclophosphamide and ofatumumab were presented
at the 2013 American Society of Hematology 2013 annual meeting. This combination was used because of the reported efficacy of chemo immunotherapy (CIT), the combined used of chemotherapy with monoclonal antibodies, in CLL as well as the activity and toxicity of combinations in which pentostatin is used. Patients (n = 49) were included in the analysis. The overall response rate, the primary end point, was 93.7%. The efficacy of the ofatumumab-based CIT compared favourably with rituximab-based CIT regimens that have been used in the past.
For more information, click here.